AnaptysBio (ANAB) Fundamental Analysis: Revenue, Earnings & Valuation

3.62 / 10

Netural

Fundamental rating is Neutral with a 3.6/10 score, indicating poor quality. Cash‑MV and inventory turnover are strengths, while Revenue‑MV and PB‑ROE lag, dragging valuation. Overall, fundamentals appear challenging despite some positive cash and efficiency metrics.

Analysis Checks(7/10)

Revenue-MV

Value-0.61

Score1/3

Weight13.47%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value157.01

Score1/3

Weight-6.38%

1M Return-3.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.87%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight4.08%

1M Return1.69%

PB-ROE

Value3.01

Score0/3

Weight8.99%

1M Return3.23%

Income tax / Total profit (%)

Value-1.25

Score2/3

Weight2.39%

1M Return1.04%

Fixed assets turnover ratio

Value145.76

Score2/3

Weight-1.19%

1M Return-0.51%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.34%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight34.56%

1M Return12.22%

Cash-MV

Value0.74

Score2/3

Weight15.87%

1M Return5.94%

Is ANAB fundamentally strong?

ANAB scores 3.62/10 on fundamentals and holds a Fair valuation at present. Backed by its -24.49% ROE, -5.64% net margin, -124.71 P/E ratio, 44.35 P/B ratio, and 91.02% earnings growth, these metrics solidify its Netural investment rating.